Acute Coronary Syndrome Companies

Latest Acute Coronary Syndrome Companies Updates:

Abbott's Portico™ Transcatheter Mitral Valve System In November 2023, Abbott announced the initiation of a pivotal US clinical trial for its Portico™ Transcatheter Mitral Valve System, a less invasive treatment option for mitral valve regurgitation. Positive results could significantly impact the market by providing a new option for patients with this prevalent condition.

Dexa Medica's DESolve Bioabsorbable Stent Dexa Medica received FDA approval in October 2023 for its DESolve Bioabsorbable Stent, the first fully absorbable drug-eluting stent for coronary artery disease. This innovative technology offers potential advantages like reduced long-term risks and improved vessel healing.

Biotronik's Orbera Balloon System Biotronik launched its Orbera Balloon System in Europe in June 2023. This temporary intragastric balloon device helps with weight management and can be used as a bridge to improve clinical outcomes before coronary artery bypass surgery in obese patients.

List of Acute Coronary Syndrome Key companies in the market:

• Johnson & Johnson Services, Inc. (U.S.)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Portola Pharmaceuticals, Inc. (U.S.)


• AbbVie Inc. (U.S.)


• AstraZeneca (U.K)


• Amgen Inc. (U.S.)


• Bayer AG (Germany)


• DAIICHI SANKYO COMPANY, LIMITED. (Japan)


• Eli Lilly and Company (U.S.)


• GlaxoSmithKline Plc. (U.K)


• Sanofi (Paris)